S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Biden's latest bailout--terrible for America? (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Biden's latest bailout--terrible for America? (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Biden's latest bailout--terrible for America? (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
MILAN FASHION PHOTOS: Naomi Campbell stuns at Dolce&Gabbana in collection highlighting lingerie
Biden's latest bailout--terrible for America? (Ad)
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
Minnesota's would-be head of cannabis regulation quits amid reports she sold illegal products
The single greatest medical breakthrough of all time? (Ad)
After climate summit, California Gov. Gavin Newsom faces key decisions to reduce emissions back home
The threat of wildfires is rising. So are new artificial intelligence solutions to fight them
The single greatest medical breakthrough of all time? (Ad)
Giorgio Armani closes Milan Fashion Week with good vibes and familiar guests in the front row
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:DCPH

Deciphera Pharmaceuticals (DCPH) Stock Forecast, Price & News

$12.88
-0.37 (-2.79%)
(As of 09/22/2023 ET)
Compare
Today's Range
$12.79
$13.41
50-Day Range
$12.82
$15.48
52-Week Range
$12.73
$22.76
Volume
273,293 shs
Average Volume
388,506 shs
Market Capitalization
$1.02 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.71

Deciphera Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.63 Rating Score
Upside/​Downside
76.4% Upside
$22.71 Price Target
Short Interest
Bearish
7.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.35
Upright™ Environmental Score
News Sentiment
0.84mentions of Deciphera Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.36) to ($2.17) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

471st out of 963 stocks

Pharmaceutical Preparations Industry

210th out of 458 stocks


DCPH stock logo

About Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

DCPH Price History

DCPH Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
Deciphera Pharmaceuticals: Clawing Its Way Back
Why Shares of Deciphera Pharmaceuticals Rose This Week
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
Earnings Preview: Deciphera Pharmaceuticals
DCPH - Deciphera Pharmaceuticals, Inc.
JonesTrading Remains a Hold on Deciphera Pharmaceuticals (DCPH)
See More Headlines
Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Company Calendar

Last Earnings
8/09/2023
Today
9/24/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DCPH
Fax
N/A
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.71
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+76.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.63
Research Coverage
8 Analysts

Profitability

Net Income
$-178,930,000.00
Net Margins
-129.90%
Pretax Margin
-129.40%

Debt

Sales & Book Value

Annual Sales
$144.07 million
Book Value
$5.05 per share

Miscellaneous

Free Float
75,329,000
Market Cap
$1.02 billion
Optionable
Optionable
Beta
0.69

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Steven L. Hoerter (Age 52)
    Pres, CEO & Director
    Comp: $1.24M
  • Dr. Daniel L. Flynn Ph.D. (Age 68)
    Exec. VP, Chief Scientific Officer & Founder
    Comp: $759.18k
  • Mr. Thomas Patrick Kelly J.D.Mr. Thomas Patrick Kelly J.D. (Age 52)
    Exec. VP, CFO & Treasurer
    Comp: $778.85k
  • Mr. Daniel C. Martin (Age 48)
    Sr. VP & Chief Commercial Officer
    Comp: $711.42k
  • Dr. Matthew L. Sherman M.D. (Age 67)
    Exec. VP & Chief Medical Officer
    Comp: $865.62k
  • Dr. Kevin Brodbeck Ph.D.
    Sr. VP & Chief Technical Officer
  • Jennifer Larson
    Sr. VP of Fin. & Investor Relations
  • Mr. Jeffrey M. Held J.D.
    Sr. VP & Gen. Counsel
  • Ms. Lisa Amaya Price
    Sr. VP & Chief HR Officer
  • Ms. Jama Pitman (Age 44)
    Sr. VP of Regulatory, Quality & Portfolio Management













DCPH Stock - Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 1 sell rating, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DCPH shares.
View DCPH analyst ratings
or view top-rated stocks.

What is Deciphera Pharmaceuticals' stock price forecast for 2023?

8 equities research analysts have issued 1 year price targets for Deciphera Pharmaceuticals' stock. Their DCPH share price forecasts range from $9.00 to $30.00. On average, they expect the company's stock price to reach $22.71 in the next twelve months. This suggests a possible upside of 76.4% from the stock's current price.
View analysts price targets for DCPH
or view top-rated stocks among Wall Street analysts.

How have DCPH shares performed in 2023?

Deciphera Pharmaceuticals' stock was trading at $16.39 at the beginning of 2023. Since then, DCPH shares have decreased by 21.4% and is now trading at $12.88.
View the best growth stocks for 2023 here
.

When is Deciphera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our DCPH earnings forecast
.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) issued its earnings results on Wednesday, August, 9th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.05. The firm earned $38.30 million during the quarter, compared to analysts' expectations of $36.09 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 47.99% and a negative net margin of 129.90%. The firm's revenue was up 17.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.60) EPS.

What ETFs hold Deciphera Pharmaceuticals' stock?

ETFs with the largest weight of Deciphera Pharmaceuticals (NASDAQ:DCPH) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).Range Cancer Therapeutics ETF (CNCR).

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.96%), Braidwell LP (4.63%), State Street Corp (4.02%), Goldman Sachs Group Inc. (2.69%), Dimensional Fund Advisors LP (1.79%) and Nuveen Asset Management LLC (1.72%). Insiders that own company stock include Brightstar Associates Llc, Daniel C Martin, Daniel Lee Flynn, Dennis Leo Walsh, Franklin Stuart Friedman, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, Steven L Hoerter and Thomas Patrick Kelly.
View institutional ownership trends
.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $12.88.

How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $1.02 billion and generates $144.07 million in revenue each year. The company earns $-178,930,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis.

How many employees does Deciphera Pharmaceuticals have?

The company employs 300 workers across the globe.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for the company is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.

This page (NASDAQ:DCPH) was last updated on 9/24/2023 by MarketBeat.com Staff

My Account -